All In Biotech

Drug Trial Radar · NCT07074886

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

A Phase II, Randomized, Open-label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients With Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 193 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

193

Actual

Start

Nov 13, 2025

Primary completion

Sep 17, 2026

Study completion Mar 31, 2030

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.

Conditions

  • Multiple Sclerosis

Interventions

  • Ocrelizumab Test FormulationDrug

    Ocrelizumab test formulation will be administered as per the schedule specified in the respective arm.

  • Ocrelizumab Reference FormulationDrug

    Ocrelizumab reference formulation will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Serum Concentration-time Curve Over the First 12 Weeks Post-dose (AUC0-12W) of OcrelizumabTime frame: Up to 12 weeks
  2. Maximum Serum Concentration (Cmax) of OcrelizumabTime frame: Up to 12 weeks

Locations

49 sites in 9 countries. Site status is shown where the registry gives one.

  • Profound Research, LLC

    Carlsbad, California

  • Advanced Neurology of Colorado, LLC

    Fort Collins, Colorado

  • Neurology Associates PA

    Maitland, Florida

  • University of South Florida

    Tampa, Florida

  • Johns Hopkins University School Of Medicine

    Baltimore, Maryland

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • SUNY Upstate Medical University

    Syracuse, New York

  • Hope Neurology

    Knoxville, Tennessee

  • Swedish Medical Center

    Seattle, Washington

  • Instituto Médico Rivarola IMR

    Buenos Aires, Argentina

  • IME - Instituto Médico Especializado

    Buenos Aires, Argentina

  • Sanatorio del Sur S.A.

    San Miguel de Tucumán, Argentina

  • Centro de Especialidades Neurológicas y Rehabilitación - CENyR

    CABA, Buenos Aires, Argentina

  • Focus CECIC

    CABA, CABA / Buenos Aires, Argentina

  • INECO Neurociencias Orono

    Rosario, Santa Fe Province, Argentina

  • Santa Casa de Misericordia de Salvador

    Salvador, Estado de Bahia, Brazil

  • Instituto de Neurologia de Curitiba

    Curitiba, Paraná, Brazil

  • Cpn - Centro de Pesquisa Neurologica Porto Alegre Ltda

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto do Cerebro do Rio Grande do Sul

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinica Neurológica e Neurocirúrgica de Joinville

    Joinville, Santa Catarina, Brazil

  • Centro de Pesquisas Clinicas - CPCLIN

    São Paulo, São Paulo, Brazil

  • Hôpital Guillaume et René Laënnec

    Nantes, France

  • CHU de Nimes - Hopital Universitaire Caremeau

    Nîmes, France

  • Charite - Universitätsmedizin Berlin

    Berlin, Germany

  • St. Josef-Hospital, Klinik für Neurologie

    Bochum, Germany

  • Universitätsklinikum "Carl Gustav Carus", Zentrum für Klinische Neurowissenschaften

    Dresden, Germany

  • Universitätsklinikum Tübingen, Zentrum für Neurologie

    Tübingen, Germany

  • AO.U. Policlinico Riuniti Foggia

    Foggia, Apulia, Italy

  • AOU dell Universita degli Studi della Campania Luigi Vanvitelli Piazza Luigi Miraglia 2

    Naples, Campania, Italy

  • Università degli studi della Campania Luigi Vanvitelli

    Naples, Campania, Italy

  • Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla

    Rome, Lazio, Italy

  • NCL Institute Neuroscience

    Rome, Lazio, Italy

  • Fond. Istituto Neurologico C.Besta

    Milan, Lombardy, Italy

  • IRCCS Istituto Neurologico Neuromed

    Pozzilli, Molise, Italy

  • Inovacion y Desarrollo en ciencias de la salud

    Mexico City, Mexico CITY (federal District), Mexico

  • Neurociencias Prisma, A.C

    San Luis Potosí City, San Luis Potosí, Mexico

  • Neurociencias Estudios Clinicos S.C.

    Culiacán, Sinaloa, Mexico

  • ProNeuro Centrum Medyczne

    ?ory, Poland

  • Neurocentrum Bydgoszcz sp z o.o

    Bydgoszcz, Poland

  • Centrum Neurologii Krzysztof Selmaj

    Lodz, Poland

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.